6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

What this trial studies

Thymic epithelial tumors (TETs) are rare mediastinal malignancies. Locally advanced, potentially resectable TETs present a significant clinical challenge, with limited prospective data on optimal neoadjuvant chemotherapy duration. Retrospective data from Shanghai General Hospital suggest that 6 cycles of neoadjuvant chemotherapy may yield higher objective response rates (75% vs 33.3%) and R0 resection rates (68.75% vs 33.33%) compared to 3 cycles. This is a single-center, prospective, open-label, randomized controlled trial. Eligible patients are adults (18-65 years) with histologically confirmed WHO type AB, B1, B2, B3 thymoma or thymic carcinoma (type C), AJCC TNM stage IIIA-IVA, deemed potentially resectable by multidisciplinary team (MDT) evaluation, ECOG PS 0-1, with adequate organ function, no prior anti-tumor therapy. Randomization: 1:1, stratified by histological subtype (type B vs type C), using central randomization with block size 4. Treatment: * Type B thymoma arm: cisplatin 50 mg/m² + doxorubicin 50 mg/m² + cyclophosphamide 500 mg/m², Q3W * Type C thymic carcinoma arm: nab-paclitaxel 200 mg/m² + carboplatin AUC 5, Q3W * Control group: 3 cycles; Experimental group: 6 cycles Imaging assessment (RECIST 1.1) every 2 cycles. CR/PR: proceed to surgery; SD: continue chemotherapy; PD: radical radiotherapy. Post-operative radiotherapy as indicated (R0: 45-50 Gy; R1: 54 Gy; R2: 60-70 Gy). Primary endpoint: Event-Free Survival (EFS), defined as time from randomizatio…

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytologically confirmed thymic epithelial tumor (thymoma or thymic carcinoma)
* Locally advanced, potentially resectable disease (Masaoka-Koga stage III or IVA), as evaluated by a multidisciplinary team (MDT) including thoracic surgery and thoracic oncology
* Age 18 to 65 years
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet count ≥100×10⁹/L, hemoglobin ≥90 g/L
* Adequate liver function: total bilirubin ≤1.5× upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN
* Adequate renal function: creatinine clearance ≥50 mL/min (Cockcroft-Gault formula)
* No prior systemic anticancer therapy for thymic epithelial tumor
* At least one measurable lesion per RECIST v1.1
* Willing to accept randomization and able to comply with study procedures
* Written informed consent obtained prior to any study-related procedures

Exclusion Criteria:

* Prior chemotherapy, targeted therapy, or immunotherapy for thymic epithelial tumor
* Prior thoracic radiation therapy
* Active autoimmune disease requiring systemic treatment within the past 2 years
* Known hypersensitivity or contraindication to study drugs (cisplatin, epirubicin, etoposide, ifosfamide, or any component of these formulations)
* Severe cardiac dysfunction: New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction (LVEF) \<50%
* Active hepatitis B (HBsAg positive with HBV DNA ≥2000 IU/mL), active hepatitis C, or known HIV infection
* Pregnancy or lactation; women of childbearing potential unwilling to use adequate contraception
* Other malignancy within 5 years prior to enrollment, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix
* Uncontrolled active infection requiring systemic therapy
* Any condition that, in the investigator's judgment, would preclude safe participation in the study

Where it's running

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China

Study contacts

• Principal investigator: Fan Jiang, MD, PhD — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• Study coordinator: Fan Jiang, MD, PhD
• Email: fan_jiang@sjtu.edu.cn
• Phone: 86-21-63240090

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sonrotoclax plus azacitidine in high-risk MDS with increased blasts-2

  This study tests whether adding sonrotoclax to azacitidine can help people with newly diagnosed high-risk MDS with increased blasts-2 see better disease control and tolerable safety.

  Recruiting Phase 1/2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 5 other locations · NCT07885397

• Acupuncture to Improve Sleep and Reduce Pain After Lung Cancer Surgery (VATS)

  This trial tests whether acupuncture given around surgery can improve sleep and lessen chronic pain for adults undergoing video-assisted thoracoscopic lung cancer removal.

  Recruiting at 2 sites Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 1 other locations · NCT07662733

• STN-targeted non-invasive brain stimulation for Parkinson’s symptoms

  A non-invasive procedure called tTIS is tested in people with Parkinson’s to see if it helps motor and non-motor symptoms.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07625540

• Nimotuzumab plus Immunotherapy and Chemotherapy before surgery for locally advanced head and neck cancer

  This phase 2 trial tests whether adding nimotuzumab to immunotherapy and chemotherapy before surgery helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07601737

• Risk predictor for new urinary incontinence after prolapse surgery

  This study tests a model to predict which women might develop new stress urinary incontinence after pelvic organ prolapse repair.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07601282

• See if EUS-SWQ can accurately detect and grade liver fibrosis in adults with chronic liver disease

  This study tests whether the endoscopic ultrasound shear wave quantification (EUS-SWQ) can match liver biopsy results in adults with chronic liver disease to diagnose and stage fibrosis, and whether it offers safety and measurement advantages over FibroScan.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07588854

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.